Cefodizime displays modest yet variable inhibitory effects against Citrobacter species, including Citrobacter freundii, and Serratia marcescens. It also inhibits other Gram-negative bacteria, such as Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Neisseria meningitidis. Cefodizime is a bactericidal antibiotic with a strong affinity for penicillin-binding proteins 1A/B, 2, and 3 in E. coli. In vitro, the concentrations of Cefodizime required for bactericidal activity against susceptible strains of both Gram-positive and Gram-negative bacteria are generally comparable to the minimum inhibitory concentrations.[1]

Cefodizime (50 mg/kg; S.C.; single; experimentally-induced K. pneumoniae respiratory tract infections in mice) exhibits activity comparable to Cefotaxime and Ceftazidime and surpassing that of Cefoperazone, Latamoxef, Cefuroxime, or cefazolin for the initial 8 hours. In contrast to these cephalosporins, Cefodizime maintains significant bactericidal activity for a duration of at least 48 hours after a single injection. Although Cefodizime can no longer be detected in the serum, it achieves complete bacterial clearance from the lungs within 48 hours in 50% of the mice.[1]